AOBiome Therapeutics
@aobiome.com
AOBiome is a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other diseases. Our proprietary product candidates harness a strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria, or AOB, a human commensal with well-understood and well-characterized biochemical properties that are critical to human health. We believe that the application of AOB has the potential to restore critical biological and biochemical processes through the symbiotic relationship between humans and this naturally-existing bacteria to address significant clinical need at various stages of disease. We have six ongoing clinical programs in acne vulgaris, or acne, atopic dermatitis, or eczema, rosacea, allergic rhinitis, migraine and hypertension, and multiple ongoing preclinical programs, including ones addressing pulmonary and gastrointestinal disorders.
AOBiome Therapeutics's Company Logos
AOBiome Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#0081A2
Deep Cerulean
0, 129, 162
192, 100, 32
100, 20, 0, 36
#FBF5ED
Linen
251, 245, 237
34, 64, 96
0, 2, 6, 2
#005A87
Orient
0, 90, 135
200, 100, 26
100, 33, 0, 47
About AOBiome Therapeutics
AOBiome Therapeutics is a groundbreaking brand that focuses on the impact of ammonia oxidizing bacteria (AOB) on inflammatory conditions and related systemic effects. The brand recognizes the adverse effects of the modern environment on human physiology and aims to identify significant therapeutic opportunities to restore balance in the body. AOBiome believes that a well-functioning microbiome is crucial for human health.
When microorganisms become imbalanced or dysbiotic, it can lead to a higher susceptibility to diseases or faulty immune responses. To address this issue, AOBiome reintroduces AOB, which play a critical role in the nitrogen cycle. AOB consume ammonia and produce nitric oxide (NO) and nitrite, both of which are vital for various biological systems.
NO, in particular, has been hailed as the Molecule of the Year and has anti-inflammatory properties. In addition to modulating nitrite and regulating cytokines associated with immune response, AOB also reduces the populations of pathogenic bacteria commonly associated with diseases like eczema and acne. AOBiome has observed promising results in their clinical trials using B244, a live strain of Nitrosomonas eutropha.
Their formulations tailored to specific inflammatory conditions have exhibited a high tolerability profile without any serious adverse events. AOBiome's groundbreaking science and innovative approach make them a leading brand in the field of microbiome therapeutics
Company type
Privately Held
Year founded
2013
Company size
2-10 employees
